Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electroconvulsive Therapy01:30

Electroconvulsive Therapy

685
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
685
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

1.5K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Divergent psychological stress response patterns to the COVID-19 pandemic in psychiatric patients with vs. without PTSD: A real-world exploratory study.

PloS one·2025
Same author

Dissecting neural correlates of theory of mind and executive functions in behavioral variant frontotemporal dementia.

Alzheimer's research & therapy·2024
Same author

Automated remote speech-based testing of individuals with cognitive decline: Bayesian agreement of transcription accuracy.

Alzheimer's & dementia (Amsterdam, Netherlands)·2024
Same author

NMDAR1 autoantibodies as potential biomarkers for schizophrenia phenotyping.

The lancet. Psychiatry·2024
Same author

Association of Neurogranin and BACE1 With Clinical Cognitive Decline in Individuals With Subjective Cognitive Decline.

Neurology·2024
Same author

Functional Neuroligin-2-MDGA1 interactions differentially regulate synaptic GABA<sub>A</sub>Rs and cytosolic gephyrin aggregation.

Communications biology·2024

Related Experiment Video

Updated: Dec 30, 2025

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.4K

[Vagus Nerve Stimulation for Affective Disorders].

Maxine Dibué-Adjei1,2, Marcel Alexander Kamp1, Jonathan Vogelsang3

  • 1Neurochirurgische Klinik, Heinrich Heine Universität Düsseldorf.

Fortschritte Der Neurologie-Psychiatrie
|January 28, 2020
PubMed
Summary

Vagus nerve stimulation (VNS) shows long-term efficacy for treatment-resistant depression (TRD). While short-term results are inconclusive, sustained benefits are observed over five years, though patient selection remains a challenge.

More Related Videos

Author Spotlight: Exploring the Effects of Transauricular Vagus Nerve Stimulation
04:59

Author Spotlight: Exploring the Effects of Transauricular Vagus Nerve Stimulation

Published on: January 19, 2024

3.4K
Laboratory Administration of Transcutaneous Auricular Vagus Nerve Stimulation taVNS: Technique, Targeting, and Considerations
06:31

Laboratory Administration of Transcutaneous Auricular Vagus Nerve Stimulation taVNS: Technique, Targeting, and Considerations

Published on: January 7, 2019

41.0K

Related Experiment Videos

Last Updated: Dec 30, 2025

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.4K
Author Spotlight: Exploring the Effects of Transauricular Vagus Nerve Stimulation
04:59

Author Spotlight: Exploring the Effects of Transauricular Vagus Nerve Stimulation

Published on: January 19, 2024

3.4K
Laboratory Administration of Transcutaneous Auricular Vagus Nerve Stimulation taVNS: Technique, Targeting, and Considerations
06:31

Laboratory Administration of Transcutaneous Auricular Vagus Nerve Stimulation taVNS: Technique, Targeting, and Considerations

Published on: January 7, 2019

41.0K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Medical Technology

Background:

  • Vagus nerve stimulation (VNS) is an established treatment for drug-resistant epilepsy.
  • Depression is a common comorbidity in epilepsy, and VNS has shown positive effects.
  • VNS received European approval for treatment-resistant depression (TRD) in 2001.

Purpose of the Study:

  • To systematically review recent publications and guidelines on VNS for TRD.
  • To discuss the current clinical application of VNS in TRD.
  • To assess the efficacy and challenges of VNS in TRD management.

Main Methods:

  • Systematic review of Level-2 and Level-3 studies published in the last 5 years.
  • Analysis of clinical trial data and treatment-as-usual comparisons.
  • Review of existing clinical guidelines for VNS in TRD.

Main Results:

  • Short-term efficacy of VNS in TRD patients has not been demonstrated in clinical studies.
  • Multiple studies confirm the long-term efficacy of VNS in TRD patients over a 5-year period.
  • A large investigation confirmed favorable outcomes with adjunctive VNS compared to treatment-as-usual alone.

Conclusions:

  • VNS demonstrates documented long-term efficacy in TRD, supported by Level-2 evidence.
  • Identifying specific patient subgroups likely to respond to VNS remains an area for future research.
  • Standardizing the definition of TRD is crucial for optimizing the use of neurostimulation treatments.